US OptionsDetailed Quotes

AXSM250516P115000

Watchlist

4.90
0.000.00%

15min DelayClose May 9 16:00 ET

0.00High0.00Low

Axsome Therapeutics Stock Discussion

Teddy123

Apr 1 19:05

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

$Axsome Therapeutics (AXSM.US)$
Axsome's MDD Drug Trial Reveals Unexpected Win in Sleepiness Subgroup

Teddy123

Mar 5 21:04

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

$Axsome Therapeutics (AXSM.US)$
Axsome Wins 16+ Years of Market Exclusivity for Sunosi in Patent Settlement

Teddy123

Mar 3 20:09

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

$Axsome Therapeutics (AXSM.US)$
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

Teddy123

Feb 24 20:18

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

$Axsome Therapeutics (AXSM.US)$
Can This New Migraine Drug Replace CGRP Inhibitors? Trial Shows 48x Success Rate

Teddy123

Feb 18 20:17

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

$Axsome Therapeutics (AXSM.US)$
Axsome Shatters Expectations: Record 89% Growth for Depression Drug Auvelity, Pipeline Milestones Accelerate

Teddy123

Feb 10 20:21

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

$Axsome Therapeutics (AXSM.US)$
Axsome Wins Major Victory: 15+ Years Market Protection for AUVELITY Secured in Patent Deal

Lnova

Jan 28 17:22

$Axsome Therapeutics (AXSM.US)$ watching this incase of catalyst here biopharmcatalys...
has options
nfa be careful

Clintzilla

Oct 13, 2024 03:13

$Axsome Therapeutics (AXSM.US)$ wonder what the insitutional ownership was when it went from 2 to 110 lol

Vincenttpc

Sep 25, 2024 21:07

$Axsome Therapeutics (AXSM.US)$ why the sudden drop?

Meltyy

Mar 18, 2024 16:21

FDA Development Paths

$Pfizer (PFE.US)$ $Novo-Nordisk A/S (NVO.US)$ $Axsome Therapeutics (AXSM.US)$ $Macrogenics (MGNX.US)$
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...

No comment yet